Summit Therapeutics ROA - Return on Assets 2015-2024 | SMMT

Summit Therapeutics return on assets for the quarter ending September 30, 2024 was -64.

  • Summit Therapeutics average return on assets for 2023 was -207.55, a 232.29% decline from 2022.
  • Summit Therapeutics average return on assets for 2022 was -62.46, a 9.24% increase from 2021.
  • Summit Therapeutics average return on assets for 2021 was -68.82, a 1.43% decline from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

Summit Therapeutics ROA - Return on Assets 2015-2024 | SMMT

  • Summit Therapeutics average return on assets for 2023 was -207.55, a 232.29% decline from 2022.
  • Summit Therapeutics average return on assets for 2022 was -62.46, a 9.24% increase from 2021.
  • Summit Therapeutics average return on assets for 2021 was -68.82, a 1.43% decline from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.8B
Takeda Pharmaceutical (TAK)$42.6B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.1B
Astellas Pharma (ALPMY)$18.3B
United Therapeutics (UTHR)$16.6B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12B
Catalent (CTLT)$11.1B
Madrigal Pharmaceuticals (MDGL)$7.6B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$6B
Ionis Pharmaceuticals (IONS)$5.4B
Crinetics Pharmaceuticals (CRNX)$5.2B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
NewAmsterdam Pharma (NAMS)$1.9B
Xencor (XNCR)$1.8B
Recursion Pharmaceuticals (RXRX)$1.6B
Evotec AG (EVO)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.5B
Indivior (INDV)$1.5B
Guardian Pharmacy Services (GRDN)$1.5B
Ocular Therapeutix (OCUL)$1.4B
ARS Pharmaceuticals (SPRY)$1.4B